Pharmaceutical manufacturers hold Africa business ethics and integrity seminar

The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) has held a two-day business ethics and integrity seminar for healthcare industry practitioners to help uphold worldwide ethical standards.

The seminar which brought together over 100 Pharma industry management and healthcare professionals, medical and scientific advisors received training on how to implement compliance programmes.

It was under the theme; “Business Integrity Days” and participants from healthcare industry included representatives from national pharmaceutical trade associations, ethics and compliance professionals, general managers, healthcare professionals, medical and scientific advisors as well as in-house counsels and sales representatives.

The seminar formed part of the IFPMA’s mission to support efforts worldwide to uphold ethical standards also discussed the progress Ghana and other African countries have been making in raising their standards in the ethics and business integrity space, which is contributing to IFPMA’s goal to create a level playing field in Africa.

IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s two million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

See Also:  Resuscitating Africa’s health care

The programme provided practical training on how to interact with healthcare professionals including doctors, nurses, and pharmacists with regards to promotional and medical information, how to interact with patient organisations, and how to set up and run successful compliance programmes.

Discussants including, Mr. Charles Fordjour, CEO of PharmaSymbiosis and Mr. William Ofori , Director of Astra Zeneca agreed that fake products undermine patient’s trust in healthcare systems and called on state authorities to help prevent fake drugs from eroding the trust between patients, healthcare professionals and manufacturers of genuine medicines.
The World Health Organisation estimates that as much as 30% of drugs on the Ghanaian market are fake.

A press statement copied to the B&FT acknowledged that an efficient healthcare system depends on mutual trust between manufacturers of medicines and vaccines, governments and health authorities, healthcare professionals and patients and that the challenge is frequently to apply business ethics and integrity into the day to day reality of the healthcare community.

Participants were informed about the new IFPMA Code of Practice to be launched in January 2019.

Participants received training on the local implementation of the soon to be launched new IFPMA Code of Practice. The Code aims to build trust within the healthcare community and the public, guiding all the companies and associations who are members of IFPMA to operate, act and communicate in an ethical manner.

See Also:  Corruption is Ghana’s number one problem - Martin Amidu

Since it was first drawn up in 1981, the Code has been constantly revised in order to keep up with society’s expectation for the research-based pharmaceutical industry.
This latest sixth edition, coming into force on January 1, 2019, includes a global ban on gifts and promotional aids for prescription-only medicines.

Thomas Cueni, Director General of the IFPMA, explained: “Society’s expectations of the R&D-based biopharmaceutical industry, quite rightly, constantly raise the bar.
We need to meet these expectations and live up to our commitments wherever we operate in the world, to win and retain the trust patients place in our products.

It is important that we train and offer guidance to our members companies and associations about the Code of Practice.

We are pleased that this event has attracted such a high level of engagement, which clearly demonstrates a keen desire among medicine manufacturers and healthcare professionals to behave ethically”.

Article Rating
Notify of
Inline Feedbacks
View all comments